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Abstract
The N-acetyltransferase-2 gene (NAT-2)
has been associated with Parkinson’s
disease. The genotype associated with
slow acetylation has been reported to be
increased in patients with Parkinson’s
disease. Three mutant alleles M1,M2, and
M3 of NAT-2 were investigated in 80
patients with idiopathic Parkinson’s dis-
ease and 161 age matched randomly
selected controls from a prospective
population based cohort study. The allelic
frequencies and genotypic distributions in
patients were very similar to those found
in controls. In controls the frequency of
the wild type allele increased significantly
with age suggesting that the mutant alleles
are associated with an increased risk of
mortality. These findings suggest that
NAT-2 polymorphism is not a major
genetic determinant of idiopathic Parkin-
son’s disease, but may be a determinant of
mortality in the general population.
(J Neurol Neurosurg Psychiatry 1999;67:518–520)
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Parkinson’s disease is a common neurodegen-
erative disorder among elderly people.1 2 The
aetiology of Parkinson’s disease still remains
largely unknown but most likely results from
interaction between genetic and environmental
factors.3–5 Several functionally relevant poly-
morphisms in xenobiotic metabolism have
been studied in relation to patients with
Parkinson’s disease, but with no consistent
results.6 7 Explanations for these inconsisten-
cies include diVerent methodologies, diVerent
diagnostic criteria, poor selection of control
groups, and small sample sizes. Recently, an
association of slow acetylators for NAT-2 with
Parkinson’s disease was reported.8 NAT-2,
which maps to chromosome 8p22,9 10 is associ-
ated with speed of acetylation of certain drugs
and xenobiotics.9 11 Slow acetylators are homo-
zygous for any of the mutant alleles and may be
more susceptible to low level environmental
exposure to neurotoxins.8 The finding of an
increased frequency of patients homozygous
for the NAT-2 mutations is compatible with the
view that patients with Parkinson’s disease may
be less capable of handling certain endogenous
or exogenous toxins.12 However, the findings
on NAT-2 were not confirmed.13 The aim of
this study was to investigate the possible
association of NAT-2 polymorphism in idio-
pathic Parkinson’s disease.
Methods
The study formed part of the Rotterdam study,
a prospective population based cohort study on
the frequency, aetiology, and prognosis of
chronic diseases. The cohort exists of 7983
independently living or institutionalised inhab-
itants from a suburb of Rotterdam, The Neth-
erlands, aged 55 years or older. The study
started in June 1990 and has been described
extensively elsewhere.14 Informed consent was
obtained from each participant and the study
was approved by the medical ethics committee
of Erasmus University, Rotterdam. Partici-
pants were screened at baseline (1990–3) and
at follow up (1993–4) for symptoms of parkin-
sonism by study physicians. All screen positives
had a diagnostic investigation by a neurologist.
Parkinson’s disease was diagnosed in persons
with at least two out of four cardinal signs
(resting tremor, bradykinesia, rigidity, and pos-
tural disturbances) and no other apparent
cause of parkinsonism.2 In the Rotterdam
study 97 prevalent and 35 incident patients
with Parkinson’s disease were identified until
1994. Blood samples for DNA extraction and
genotyping were available for 80 patients (68
prevalent patients and 12 incident patients,
mean age 77.3 (SD 8.3); range 57.5–99.2; 27
men, 53 women). For each patient we ran-
domly selected two age matched ( within 5
years) controls (mean age 76.8 (SD 8.3); range
57.9–98.8, 63 men and 98 women) from the
same study population who did not have
Parkinson’s disease and of whom baseline data
regarding smoking history as well as blood
samples were available. A polymerase chain
reaction (PCR) was conducted using specific
PCR primers for NAT-2.15 The amplification
products were digested using restriction en-
zymes, separated on an agarose gel and visual-
ised with ultraviolet light. We investigated the
genotype of NAT-2 using KpnI, TaqI, and
BamHI for the three mutant alleles M1, M2,
and M3 and the wild type allele of NAT-2.8
Genotyping was performed on coded samples
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without knowledge of the clinical diagnosis of
the patients. The mutations M1, M2, and M3
account for most of the slow acetylators in
white patients.16 Slow acetylators were defined
as carrying any two of the mutant alleles M1,
M2, and M3. Allele frequencies were deter-
mined by counting alleles and calculating sam-
ple proportions. Allele frequencies and geno-
type frequencies were compared using ÷2
statistics.
Results
Genotype distributions were in Hardy-
Weinberg equilibrium. Frequencies of muta-
tions in patients and controls and stratified on
age are listed in the table. Overall, the mutation
frequencies were similarly distributed among
patients and controls.
The proportion of slow acetylators in the
youngest age category, 55–64 years, was
significantly lower in patients than controls. An
interesting finding was that the frequency of
the wild type allele in controls increased
significantly with age (p trend<0.001).
Discussion
Our results do not confirm the association
between the slow acetylator genotype for
NAT-2 and Parkinson’s disease as was found
previously.8 Sample size calculations with a 5%
significance level showed that we had a power
of 90% in our study to detect diVerences in
genotype frequencies at an odds ratio level of
2.5 for slow acetylators as was found in the
study of Bandmann et al.8 This study was based
on pathologically proved Parkinson’s disease,
whereas we used clinical diagnostic criteria to
assess Parkinson’s disease. It might be consid-
ered that we misclassified some patients in our
study and that this has biased our estimates. It
is highly unlikely, however, that the resulting
bias, if any, would be big enough to explain the
discrepant findings. Moreover, the overall
frequencies of slow acetylators in patients and
controls found in our study are similar to that
found in other studies.13 17
There are several other possible explanations
for the discrepancy between our findings and
those of Bandmann et al.8 Firstly, they reported
a significant association between NAT-2 poly-
morphism and familial Parkinson’s disease, but
not with sporadic Parkinson’s disease. How-
ever, the frequency of the slow acetylator geno-
type in sporadic Parkinson’s disease in their
initial analysis was significantly higher than
controls (odds ratio=2.45; p=0.003) and after
correction for multiple comparison the point
estimate of the association remained the same
but only became of borderline significance
(odds ratio=2.45; p=0.06). Secondly, the
association between NAT-2 and Parkinson’s
disease may not be due to a causal relation but
rather to the NAT-2 gene being in linkage dis-
equilibrium with a neighbouring gene that is
involved in the aetiology of Parkinson’s
disease. This explanation is in line with the
finding of a lower proportion of slow acetyla-
tors in the early onset group in the present
study whereas Bandmann et al found a higher
proportion of slow acetylators in patients with
Parkinson’s disease compared with controls.
Thirdly, their controls came from a heteroge-
neous population submitted to the United
Kingdom Parkinson’s Disease Brain Bank and
the brain bank at the institute of Psychiatry,
London, UK and were not matched for ethnic
background. This could explain the relatively
low frequency of slow acetylators found in
their control population compared with our
study and others,13 17 and may have introduced
some bias. Fourthly, we found that the
frequency of the wild type allele in controls
increased significantly with age suggesting that
the mutant alleles are associated with an
increased risk of mortality, possibly because of
the increased risk of cancer for mutation
carriers.7 18 This suggests that bias may be
introduced if cases and controls are not
matched for age which was the case in the
series of Bandmann et al,8 in which the mean
age of the control population (77.1 years) was
almost 9 years higher than the mean age
from familial patients (68.4 years). A final
explanation could be that slow acetylators are
not only more susceptible to neurotoxins
which are inactivated by an acetylation
reaction,8 but are simultaneously less suscepti-
ble to potential neurotoxins which are acti-
vated by acetylation. This dual activation-
detoxification of the NAT-2 polymorphism
makes the interpretation of any association
debatable.19
The findings of this population based study
suggest that NAT-2 polymorphism is not a
major genetic determinant of idiopathic Par-
kinson’s disease, but may be a determinant of
mortality in the general population.
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NEUROLOGICAL STAMP
Charles Louis Alphonse Laveran (1845-1922)
The pathogenic agent for malaria was discovered by
Alphonse Laveran, a French military physician in Constan-
tine, Algeria in 1880. In Algeria Laveran often performed
necropsies on malaria victims. Numerous pigmented bod-
ies and other bodies at the edge of which were moveable
filaments or flagella were seen in their blood.The rapid and
varied movement of these flagella indicated to Laveran that
they must be parasites. He found such parasites in 148 out
of 192 cases and concluded they were the cause of malaria.
He called the parasite Oscilliaria malariae but the Italian
name Plasmodium later won favour.
Laveran found that the pathological pigments could also
be found in the brain, spleen, and liver of patients who had
died from malaria. His work was not immediately
accepted. In 1884 Laveran persuaded Pasteur and Emile
Roux of the correctness of his views when a rare case of
malignant malaria in a soldier in Paris gave him the oppor-
tunity to demonstrate the parasite. He suggested in 1884
that the vector was the mosquito but it was the work of
Patrick Manson, Giovanni Grassi, and Ronald Ross which
elucidated the life cycle of the parasite and the transmission
of the disease by the anopheles mosquito. Ross, who
discovered the malaria protozoa in the stomach wall and
salivary glands of the anopheles mosquito in 1897, was
awarded the Nobel prize for this discovery in 1902, 5 years
before his teacher Laveran.
By early 1890 Laveran’s work brought him recognition
from the leading scientific and medical societies of Paris as
well as more broadly in the international scientific
community, but the army military medical service did not
acknowledge his contributions in the way that he had
hoped. Deeply dissatisfied he resigned from the military
medical service on 15 December 1896. The Pasteur Insti-
tute in Paris oVered him laboratory space and independ-
ence, naming him Honorary Chief of Research. Laveran
was a powerful influence in developing research in tropical
diseases. With the trypanosomes he elucidated the life
cycles and disease activities as well as therapeutic and pro-
phylactic measures against the illnesses that they caused.
He contributed particularly to the understanding of the
transmission of sleeping sickness. He also studied the para-
sites of Leishmania. In 1884 Laveran published Traité des
fièvres palustres, and won the Nobel Prize for Physiology or
Medicine in 1907, for demonstrating the role played by
protozoa in causing disease. With the prize money he
founded a laboratory of tropical medicine at the Pasteur
Institute.
During the first world war, apart from being a member of
a Commission on Hygiene and Prophylaxis, he organised
preventive measures against malaria in areas where French
troops would encounter the disease. In 1912 he was made
Commander of the Legion of Honour. His medical
colleagues appointed him Honorary Director of the
Pasteur Institute in 1915 on his 70th birthday and
President of the Academy of Medicine in 1920.
Laveran was honoured philatelically on a stamp issued
by Algeria in 1954. Laveran is shown in a military uniform
(Stanley Gibbons 327, Scott 252).
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